Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results

Abstract Background Biliary tract cancer (BTC) has a poor prognosis and lacks a standardized second-line therapy. Vascular endothelial growth factor (VEGF), fibroblast growth factor receptor (FGFR) 4, and platelet-derived growth factor receptor (PDGFR) are highly expressed in BTC. Therefore, lenvati...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Makoto Ueno, Masafumi Ikeda, Takashi Sasaki, Fumio Nagashima, Nobumasa Mizuno, Satoshi Shimizu, Hiroki Ikezawa, Nozomi Hayata, Ryo Nakajima, Chigusa Morizane
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2020-11-01
Цуврал:	BMC Cancer
Нөхцлүүд:	Lenvatinib Biliary tract cancer Cholangiocarcinoma Gallbladder cancer Ampulla of Vater
Онлайн хандалт:	http://link.springer.com/article/10.1186/s12885-020-07365-4
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!